

PharmLabs San Diego Certificate of Analysis



Sample PRPL Pillows THCh Disposable

Delta9 THC	ND	THCa	ND	Total THC (THC + THCa)	ND	Delta8 THC	65.25%
------------	----	------	----	------------------------	----	------------	--------

Sample ID	SD240529-005 (94550)	Matrix	Concentrate (Inhalable Cannabis Good)
Tested for	Eighty Six Brand	Received	May 28, 2024
Sampled	-	Reported	Jun 03, 2024
Analyses executed	CANX, D9C	Unit Mass (g)	2.0

Summary D9C: The total Δ9-THC content in this sample is 0.00%. For the most accurate Δ9-THC concentration, refer to the GC MS/MS section of this COA. This sample was tested using HPLC and GC MS/MS. HPLC analysis can yield inconsistent results for Δ8-THC and Δ9-THC due to isomer interference. GC MS/MS was employed to avoid this issue. Please note, if THCa is present, the Δ9-THC level measured by GC MS/MS might be higher due to decarboxylation.

D9C - D9 Confirmation Analysis

Analyzed Jun 03, 2024 | Instrument GC MS/MS | Method SOP-041 D9C
The expanded Uncertainty of the analysis is approximately ±7.806% at the 95% Confidence Level

Analyte	LOD ppb	LOQ ppb	Result %	Result mg/g	Result mg/Unit
Δ9-Tetrahydrocannabinol (Δ9-THC)	1.462	4.432	0.00	0.00	0.00

CANX - Cannabinoids Analysis

Analyzed May 31, 2024 | Instrument HPLC-VWD | Method SOP-001
The expanded Uncertainty of the Cannabinoid analysis is approximately ±7.806% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Unit	Sample photography
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND	
Cannabidiol (CBDO)	0.002	0.007	ND	ND	ND	
Abnormal Cannabidiol (a-CBDO)	0.01	0.031	ND	ND	ND	
(+/-)-9B-Hydroxy-Hexahydrocannabinol (9b-HHC)	0.012	0.036	ND	ND	ND	
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.007	0.021	ND	ND	ND	
Cannabidiolic Acid (CBDA)	0.001	0.16	1.69	16.92	33.84	
Cannabigerol Acid (CBGA)	0.001	0.16	ND	ND	ND	
Cannabigerol (CBG)	0.001	0.16	ND	ND	ND	
Cannabidiol (CBD)	0.001	0.16	ND	ND	ND	
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.013	0.041	ND	ND	ND	
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.025	0.075	ND	ND	ND	
Tetrahydrocannabinol (THCV)	0.001	0.16	ND	ND	ND	
Δ8-tetrahydrocannabinol (Δ8-THCV)	0.021	0.064	0.26	2.55	5.10	
Cannabidiol (CBDH)	0.005	0.16	ND	ND	ND	
Tetrahydrocannabinol (Δ9-THCB)	0.013	0.038	1.14	11.45	22.90	
Cannabinol (CBN)	0.001	0.16	0.84	8.44	16.88	
Cannabidiophorol (CBDP)	0.015	0.047	ND	ND	ND	
exo-THC (exo-THC)	0.005	0.16	ND	ND	ND	
Tetrahydrocannabinol (Δ9-THC)	0.003	0.16	0.92	9.25	18.50	
Δ8-tetrahydrocannabinol (Δ8-THC)	0.004	0.16	65.25	652.49	1304.98	
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.16	ND	ND	ND	
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.16	ND	ND	ND	
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.16	ND	ND	ND	
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.16	ND	ND	ND	
Tetrahydrocannabinolic Acid (THCA)	0.001	0.16	ND	ND	ND	
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.024	0.071	1.25	12.51	25.02	
Cannabinol Acetate (CBNO)	0.014	0.043	ND	ND	ND	
Δ9-Tetrahydrocannabinol (Δ9-THCP)	0.017	0.16	ND	ND	ND	
Δ8-Tetrahydrocannabinol (Δ8-THCP)	0.041	0.16	ND	ND	ND	
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.16	ND	ND	ND	
9(S)-HHCP (s-HHCP)	0.031	0.094	ND	ND	ND	
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.16	ND	ND	ND	
9(R)-HHCP (r-HHCP)	0.026	0.079	ND	ND	ND	
9(S)-HHC-O-acetate (s-HHCO)	0.005	0.16	ND	ND	ND	
9(R)-HHC-O-acetate (r-HHCO)	0.008	0.025	ND	ND	ND	
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.067	0.204	ND	ND	ND	
Total THC (THCa * 0.877 + Δ9THC)			0.92	9.25	18.50	
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			66.17	661.74	1323.48	
Total CBD (CBDA * 0.877 + CBG)			1.48	14.84	29.68	
Total CBG (CBGA * 0.877 + CBG)			ND	ND	ND	
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	
Total Cannabinoids Analyzed			71.15	711.53	1423.06	

UJ Unidentified
ND Not Detected
N/A Not Applicable
NT Not Reported
LOD Limit of Detection
LOQ Limit of Quantification
<LOQ Detected
>ULOL Above upper limit of linearity
CFU/g Colony Forming Units per 1 gram
TNTC Too Numerous to Count



DCC license: C8-0000098-LIC
DEA license: RP0611043
ISO/IEC 17025:2017 Acc. L17-427-1



Scan the QR code to verify authenticity.

Authorized Signature

Brandon Starr

Brandon Starr, Lab Manager
Mon, 03 Jun 2024 11:59:23 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. L17-427-1



*This report shall not be reproduced except in full, without the written approval of the lab. This report is for informational purposes only and should not be used to diagnose, treat or prevent any disease. Results are only for samples and batches indicated. Results are reported on an "as received" basis, unless indicated otherwise. When a Pass/Fail status is reported, that status is intended to be in accordance with federal, state and local laws which are required for the customer to be in compliance. The measurement of uncertainty is not included in the Pass/Fail evaluation unless explicitly required by federal, state or local laws and has been reported on the certificate of analysis. Measurement of uncertainty is available upon request.